Analysis Homology Medicines, Inc. (0T6G)
5/29/2024
Analysis of Homology Medicines, Inc. (0T6G)
Homology Medicines, Inc. is showing some interesting trends based on the provided data.- The Relative Strength Index (RSI) values are consistently above 60, indicating a strong bullish momentum in the stock.
- The Moving Average Convergence Divergence (MACD) indicator is positive, suggesting that the stock is in an uptrend.
- The Moving Average (MA) indicator values are also increasing, further supporting the bullish trend.
Overall, based on the RSI, MACD, and MA indicators, it seems that Homology Medicines, Inc. is currently in a strong bullish phase with potential for further price appreciation. However, it's important to consider other factors and conduct a more in-depth analysis before making any investment decisions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided yet. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The results for the quarter ending on January 31, 2025, were released after hours. The results for the quarter ending on October 31, 2024, were not provided at the specified time. However, the results for the quarter ending on August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a decrease in quarterly revenue and earnings growth year over year.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has a beta of 1.264 and has fluctuated between a fifty-two-week low and high.
Valuation metrics show a high PEG ratio and forward PE ratio, with a relatively high price to book and price to sales ratios. The company's market capitalization and enterprise value are substantial, with moderate ratios for enterprise to EBITDA and enterprise to revenue.
The stock price summary includes moving averages, a range of fifty-two-week prices, and a beta value.
Lastly, dividends and splits data show a low payout ratio, upcoming dividend dates, and information on past splits and dividend yields.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to maintain a healthy EBITDA margin, indicating strong operational performance.
8. Overall, the financial performance of the company in terms of revenue generation has been positive and shows a growth trend.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant changes, such as common stock repurchases, debt issuances, and dividends paid.
5. Investing activities also vary, with acquisitions, investments, and capital expenditures impacting the cash flow.
6. The end cash position has been fluctuating, but overall, the company has maintained a healthy cash balance.
7. Stock-based compensation has been a significant factor in the company's cash flow activities.
8. The company has been involved in the sale and purchase of investments, impacting the cash flow statement.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a low estimate of $1.27 and a high estimate of $1.36. This shows growth compared to the EPS of $1.26 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a low estimate of $1.44 and a high estimate of $1.63. This indicates an increase from the EPS of $1.46 from the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a low estimate of $6.43 and a high estimate of $6.92. This reflects growth compared to the EPS of $6.13 from the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a low estimate of $6.40 and a high estimate of $7.90. This forecast suggests an increase from the EPS of $6.59 reported for the current fiscal year.
Overall, the analysts' estimates indicate a positive outlook for the company's earnings per share, with expected growth in both the quarterly and annual results over the specified periods.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the company is expected to experience a significant increase in growth rate compared to the past 5 years, with a particularly high growth rate projected for the next 5 years. This indicates positive expectations and potential for expansion and development in the near future.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the majority clustering around the median and average values. The current price is below both the median and average forecast, suggesting that there may be potential for the security to increase in value according to the analysts' predictions.
MACD of 0T6G
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
